IP Library Granted Patent US 12,533,257
Granted Patent B2
US 12,533,257 · App. 17/518,424 · Granted Jan 27, 2026

Ophthalmic device for drug delivery

Inventors: Malik Y. Kahook (Denver, CO); Glenn Sussman (Laguna Niguel, CA); Craig Alan Cable, II (Laguna Hills, CA)
Assignees: SpyGlass Pharma, Inc.; The Regents of the University of Colorado
A61F9/0017A61F2/147A61F2/15A61F2/16A61F2002/1681A61F2002/1683A61F2002/1689A61F2002/169A61F2002/16905A61F2002/1699A61F2220/0033A61F2230/0065A61F2250/0063A61F2250/0067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,257
App. No.
17/518,424
Granted
Jan 27, 2026
Kind
B2
Abstract

An ophthalmic implant for drug delivery. The implant includes a primary intracapsular device coupled to a secondary device, wherein, when implanted in a patient's eye, the primary intracapsular device is held in place by the patient's capsular bag and the secondary device is held in place by the primary intracapsular device. The implant may be inserted in the eye by injecting the primary intracapsular device into the eye either before or after attaching the secondary device to the primary intracapsular device, and subsequently positioning the joined secondary device and primary intracapsular device with the primary intracapsular device held in place by the patient's capsular bag and the secondary device held in place by the primary intracapsular device. The secondary device may be designed to hold a tertiary device that can be implanted and attached at the time of surgery or anytime postoperatively.

Claims (23)

1 . An ophthalmic implant, comprising:

a primary intracapsular device comprising an intraocular structure and at least one haptic comprising a first haptic being unitarily formed with and extending outwards from the intraocular structure at a first junction of the first haptic and the intraocular structure, the intraocular structure comprising an optical axis; and

a secondary intracapsular device comprising at least one drug delivery device comprising a first drug delivery device configured to attach to the first haptic, the first drug delivery device comprising a first pad including a first planar anterior surface that lies in a first plane that is perpendicular to the optical axis when attached to the first haptic, and

wherein the first pad comprises a first polymer material and at least a first therapeutic agent.

2 . The ophthalmic implant of claim 1 , wherein the at least one haptic further comprises a second haptic being unitarily formed with and extending outwards from the intraocular structure at a second junction of the second haptic and the intraocular structure, and wherein the at least one drug delivery device further comprises a second drug delivery device configured to attach to the second haptic, the second drug delivery device comprises a second pad comprising a second polymer material and at least a second therapeutic agent.

3 . The ophthalmic implant of claim 2 , wherein the second pad includes a second planar anterior surface.

4 . The ophthalmic implant of claim 2 , wherein the intraocular structure lies in a second plane that is parallel to the first plane, and wherein the second pad lies in the first plane.

5 . The ophthalmic implant of claim 1 , wherein the first drug delivery device is configured to release the at least first therapeutic agent for a period of at least six (6) months.

6 . The ophthalmic implant of claim 1 , wherein the first drug delivery device comprises an outer layer comprising a silicone material.

7 . The ophthalmic implant of claim 1 , wherein the intraocular structure further comprises a first surface feature at the first junction, the first drug delivery device configured to be retained in position by the first surface feature.

8 . The ophthalmic implant of claim 7 , wherein the first surface feature is a first flare.

9 . The ophthalmic implant of claim 8 , wherein the first surface feature is configured to resist outward movement of the first drug delivery device relative to the intraocular structure.

10 . The ophthalmic implant of claim 1 , wherein the at least first therapeutic agent comprises at least one prostaglandin analog.

11 . The ophthalmic implant of claim 1 , wherein the intraocular structure comprises an intraocular lens.

12 . The ophthalmic implant of claim 1 , wherein the intraocular structure comprises an intraocular scaffold devoid of a lens.

13 . A method comprising:

implanting the ophthalmic implant of claim 1 into an eye of a subject.

14 . The ophthalmic implant of claim 1 , wherein the first drug delivery device is embedded in an outer shell.

15 . The ophthalmic implant of claim 14 , wherein the outer shell comprises a polymer material.

16 . The ophthalmic implant of claim 15 , wherein the polymer material is silicone.

17 . The ophthalmic implant of claim 1 , wherein a portion of the first pad is permeable.

18 . The ophthalmic implant of claim 17 , wherein the portion of the first pad is an entirety of the first pad.

19 . The ophthalmic implant of claim 1 , wherein the first planar anterior surface extends across an entirety of an anterior-facing side of the first pad.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2022
From: KAHOOK, MALIK Y.; SUSSMAN, GLENN
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 061930/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2022
From: CABLE, CRAIG ALAN, II
To: SPYGLASS PHARMA, INC.
Reel/Frame 061930/0454 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2021
From: KAHOOK, MALIK Y.
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 058155/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2021
From: SUSSMAN, GLENN; CABLE, CRAIG ALAN, II
To: SPYGLASS PHARMA, INC.
Reel/Frame 058155/0730 →
CHANGE OF NAME Recorded Nov 18, 2021
From: SPYGLASS OPHTHALMICS, INC.
To: SPYGLASS PHARMA, INC.
Reel/Frame 058189/0869 →
Continuity (5)
Continuation 16516356 · Jul 19, 2019
Provisional Application 62820381 · Mar 19, 2019
Provisional Application 62719922 · Aug 20, 2018
Provisional Application 62702169 · Jul 23, 2018
Related Publication 20220054310A1 · Feb 24, 2022
References Cited (62)
US 4418431A · Feaster · 1983 [cited by examiner]
US 4648879A · Kelman · 1987 [cited by examiner]
US 5074876A · Kelman · 1991 [cited by applicant]
US 5628795A · Langerman · 1997 [cited by applicant]
US 7713299B2 · Brady et al. · 2010 [cited by applicant]
US 8652206B2 · Masket · 2014 [cited by applicant]
US 8663235B2 · Tassignon · 2014 [cited by applicant]
US 8728158B2 · Whitsett · 2014 [cited by applicant]
US 9358103B1 · Wortz et al. · 2016 [cited by applicant]
US 9364316B1 · Kahook et al. · 2016 [cited by applicant]
US 9925040B2 · Kahook et al. · 2018 [cited by applicant]
US 9937034B2 · Wanders · 2018 [cited by applicant]
US 9999595B2 · Rakic et al. · 2018 [cited by applicant]
US 20030149479A1 · Snyder et al. · 2003 [cited by applicant]
US 20060047339A1 · Brown · 2006 [cited by applicant]
US 20070026042A1 · Narayanan · 2007 [cited by applicant]
US 20070123981A1 · Tassignon · 2007 [cited by applicant]
US 20080215147A1 · Werblin · 2008 [cited by applicant]
US 20090130176A1 · Bossy-Nobs · 2009 [cited by examiner]
US 20100074942A1 · Ratner · 2010 [cited by examiner]
US 20100204788A1 · Van Noy · 2010 [cited by applicant]
US 20100204790A1 · Whitsett · 2010 [cited by applicant]
US 20110125090A1 · Peyman · 2011 [cited by applicant]
US 20110282328A1 · Ambati et al. · 2011 [cited by applicant]
US 20110313521A1 · Angelopoulos · 2011 [cited by applicant]
US 20130190868A1 · Kahook et al. · 2013 [cited by applicant]
US 20140148900A1 · Ratner et al. · 2014 [cited by applicant]
US 20140288645A1 · Cuevas · 2014 [cited by applicant]
US 20150209274A1 · Venkatraman · 2015 [cited by examiner]
US 20150238309A1 · Janser · 2015 [cited by applicant]
US 20150342729A1 · Kahook et al. · 2015 [cited by applicant]
US 20160256262A1 · Wortz et al. · 2016 [cited by applicant]
US 20160331519A1 · Kahook et al. · 2016 [cited by applicant]
US 20170119521A1 · Kahook · 2017 [cited by examiner]
US 20170296331A1 · Werblin et al. · 2017 [cited by applicant]
US 20180014928A1 · Kahook et al. · 2018 [cited by applicant]
US 20180368974A1 · Kahook et al. · 2018 [cited by applicant]
US 20200405538A1 · Mandell · 2020 [cited by examiner]
CN 102724933A · 2012 [cited by applicant]
CN 106413634A · 2017 [cited by applicant]
CN 107205814A · 2017 [cited by applicant]
EP 1543799A1 · 2005 [cited by applicant]
EP 3210572A1 · 2017 [cited by applicant]
JP H08103457A · 1996 [cited by applicant]
JP 2010516394A · 2010 [cited by applicant]
KR 1020160045129 · 2016 [cited by applicant]
WO 2008094518A1 · 2008 [cited by applicant]
WO 2014027963A1 · 2014 [cited by applicant]
WO 2016062503A2 · 2016 [cited by applicant]
WO 2016110489A1 · 2016 [cited by applicant]
WO 2017079449A1 · 2017 [cited by applicant]
WO 2018064578A1 · 2018 [cited by applicant]
WO 2018078026A1 · 2018 [cited by applicant]
WO 2018125930A1 · 2018 [cited by applicant]
Japan Patent Office, Notice of Reasons for Refusal, Application No. 2021-503568, Jul. 25, 2023, 10 pages. [cited by applicant]
Gonzalez-Chomon et al., “Drug-Eluting Intraocular Lenses”, Materials 2011, 4, 1927-1940. [cited by applicant]
Liu et al., “Intraocular lens as a drug delivery reservoir”, Curr Opin Ophthalmol, 2013, 24:53-59. [cited by applicant]
International Search Report for PCT/US2019/042515, dated Sep. 2, 2019, 9 pages. [cited by applicant]
Resul et al., “Structure-Activity Relationships and Receptor Profiles of Some Ocular Hypotensive Prostanoids”, Survey of Ophthalmology, vol. 41, Supplement 2, Feb. 1997, 6 pages. [cited by applicant]
Stjernschantz, “From PGF 2alpha-Isopropyl Ester to Latanoprost: A review of the Development of Xalatan The Proctor Lecture”, retrieved from https://iovs.arvojournals.org/article.aspx?articleid=2162219 on Aug. 16, 2018, … [cited by applicant]
China National Intellectual Propery Administration, First Office Action, Application No. 201980060177.1, Sep. 21, 2023, 19 pages. [cited by applicant]
IP Australia Office, Examination Report No. 1 for Standard Patent Application, Application No. 2019310003, Feb. 28, 2024, 3 pages. [cited by applicant]